Publications

Journal Article Epublish 37 citations
Open access — free full text available
Open access
Electronic publication date
April 27, 2021

View on Pubmed.gov 33897441 | View on doi.org 10.3389/fphar.2... | View the free full text Full text

Levofloxacin Versus Ciprofloxacin in the Treatment of Urinary Tract Infections: Evidence-Based Analysis.

Search for publications in this journal Front Pharmacol

  • Dehong Cao 1
  • Yinzhi Shen

    Search for this expert
    2
  • Yin Huang

    Search for this expert
    1
  • Bo Chen 1
  • Zeyu Chen 1
  • Jianzhong Ai 1
  • Liangren Liu

    Search for this expert
    1
  • Lu Yang

    Search for this expert
    Contact the corresponding author.
    Reported by OpenAlex: verify on the publication before relying on it.
    1
  • Qiang Wei

    Search for this expert
    Contact the corresponding author.
    Reported by OpenAlex: verify on the publication before relying on it.
    1

Abstract

Urinary tract infections (UTIs) are one of the most common bacterial infections acquired both in community and hospital. Fluoroquinolones, represented by levofloxacin and ciprofloxacin, are widely used for treatment of UTIs. However, it remains controversial for the comparison between the 2 drugs, which propelled us to conduct the first evidence-based research on this topic. To establish their relative efficacy and safety, we searched Pubmed, embase, and Web of Science for randomized controlled trials (RCTs) for UTIs. A total of 5 RCTs were finally included, involving 2,352 patients and a systematic review and meta-analysis were performed to compare the end-of-therapy and posttherapy clinical success rate, microbial eradication rate and adverse event rate. Jadad score and Review Manager 5.3.0 version were applied respectively to evaluate the study quality and heterogeneity. There was no significant difference between levofloxacin and ciprofloxacin group in end-of-therapy or posttherapy clinical success rate and microbial eradication rate ( > 0.05). As for adverse event rate, the 2 drugs were comparable and both safe for clinical use. Based on one included trial and pharmacological research, we raised hypothesis that levofloxacin was superior to ciprofloxacin for treatment of E. coli-induced chronic bacterial prostatitis (CBP) and it required a further study to prove it.

References

Int J Antimicrob Agents. 2012 Jun;40 Suppl:S37-43

J Med Microbiol. 2014 Jan;63(Pt 1):1-14

Curr Med Res Opin. 2007 Nov;23(11):2637-45

Andrology. 2016 Sep;4(5):800-7

Cited by 37 citations (total)

Journal Article

Genetic Determinants of Carbapenem and Fluoroquinolone Resistance in Isolates of Clinical Origin.

Electronic publication date April 4, 2025

Search for publications in this journal Infect Chemother

Simbiat Tolani Lawal [...] Stella Smith et al.

BACKGROUND

Antimicrobial resistance has emerged as a global public health challenge, leading to higher mortality rates from infections that were once...

Journal Article Review

Research progress of extracellular vesicles in the pathogenesis of type IIIA chronic prostatitis.

Electronic publication date March 4, 2025

Search for publications in this journal Front Immunol

Le Cheng [...] Biao Qian et al.

Chronic prostatitis is a prevalent urological condition that significantly impacts patients' quality of life. Advances in the study of Extracellular...

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

MeSH

Specialties

Copyright

Copyright © 2021 Cao, Shen, Huang, Chen, Chen, Ai, Liu, Yang and Wei.